COVID-19 vaccine industry cautions immediate action needed to remove manufacturing supply barriers to meet production targets and keep on course to equitable and fair access to COVID-19 vaccines
On the 1st anniversary of ACT-Accelerator, COVID-19 vaccine makers representing biotechnology firms, developing and developed country manufacturers renew their commitment to produce sufficient vaccines to meet world needs. Increased production output of COVID-19 vaccines is forecast and can be attributed to over 200 manufacturing deals coming online and greater efficiency of a complex process, however,...
Read moreVirtual Press Briefing following the Global COVID-19 Vaccine Supply Chain & Manufacturing Summit
This virtual press briefing was a readout of the recommendations to address manufacturing challenges.
Read moreVirtual Press Briefing following the Global COVID-19 Vaccine Supply Chain & Manufacturing Summit (Video)
Read moreBIO-DCVMN-IFPMA COVID-19 Press Briefing – April 2021
Read moreTwo days to discuss bottlenecks that must be urgently tackled for COVID-19 vaccine output of manufacturers to reach its full potential
A summit was convened in a matter of weeks by Chatham House, in collaboration with COVAX, IFPMA, DCVMN, and BIO, took place on 8-9 March 2021. A discussion document helped inform participants, gave an overview of the current COVID-19 vaccine manufacturing supply chain and identified emerging challenges. While the meeting was conducted under Chatham House rule to facilitate an...
Read moreMeeting discusses COVID-19 vaccine manufacturing bottlenecks that must be urgently tackled for C19 vaccine output to reach its full potential
9 March 2021: Chatham House, in collaboration with COVAX, IFPMA, DVCMN, and BIO, convened a Global COVID-19 Vaccine Supply Chain & Manufacturing Summit on 8th and 9th March. The unprecedented scaling up of vaccine manufacturing, from zero to billions of doses in record time, has led to shortages that are impacting the entire vaccine supply chain....
Read moreBiopharmaceutical industry welcomes COVID-19 vaccine-sharing pledges but warn challenges remain to urgently address vaccine inequity
G7 country dose sharing announcements on the back of the G20 pledges combined with vaccine makers commitment to make available 3,5 billion extra doses are an important starting point towards achieving vaccine equity. Innovative vaccine manufacturers and biotech companies at the forefront producing COVID-19 vaccines are confident if scarcity of raw materials and trade barriers...
Read moreCOVAX launches Marketplace to match buyers and sellers of critical manufacturing suppliers and speed up global access to COVID-19 vaccines through COVAX
15 July 2021 – IFPMA welcomes the launch of an innovative ‘marketplace’. The new Marketplace aims to accelerate the global production of COVID-19 vaccine doses for COVAX by matching suppliers of critical inputs with vaccine manufacturers who urgently need them to produce vaccines for fair and equitable distribution through COVAX. This initiative spearheaded by Coalition...
Read more3rd global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read moreCOVID-19 diagnostics, treatments and vaccines: Progress achieved in 2020 and insights into 2021 and beyond
Last week, IFPMA hosted the fifth and last CEO COVID-19 media briefing of 2020 with CEOs and top executives from Eli Lilly and Company, Johnson & Johnson, Pfizer and Roche. I joined the CEOs as they shared their take on progress achieved in 2020 and insights into 2021 and beyond. With this blog, I wanted...
Read more